Reliability of IUS in Crohn's Disease

Last updated: February 13, 2025
Sponsor: Centre Hospitalier Universitaire, Amiens
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Transabdominal intestinal ultrasound

Clinical Study ID

NCT06833450
PI2022_843_0006
  • Ages > 18
  • All Genders

Study Summary

Transabdominal intestinal ultrasound (IUS) is gaining acceptance as a point-of-care test to objectively assess disease activity in Crohn's disease (CD).

In order to incorporate individual parameters in a future definition of transmural healing, and for the consistent application of IUS as a modality to assess treatment outcomes and establish therapeutic targets to ensure comparability between future studies, the inter-observer agreement should be determined for all relevant parameters.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Crohn's disease evolving for at least 1 months

  • Patient older than 18 years

  • Patient covered by French national health insurance

  • Written informed consent

Exclusion

Exclusion Criteria:

  • Pregnant women or breastfeeding

  • Minor

  • Patient deprived of liberty by administrative or judicial decision or placed underjudicial protection (guardianship or supervision)

Study Design

Total Participants: 30
Treatment Group(s): 1
Primary Treatment: Transabdominal intestinal ultrasound
Phase:
Study Start date:
January 19, 2022
Estimated Completion Date:
February 28, 2026

Connect with a study center

  • CHU d'Amiens

    Amiens, 80054
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.